Traders should monitor whether 2026 revenue recovers beyond the guided range, as current outlook reflects near-term headwinds. Margin expansion and cost control are positives, but dependency on large customers creates execution risk. The ERP implementation and late-stage pipeline commercialization could be catalysts post-2026.
Price Chart
Executive Summary
Lifecore Biomedical reported strong financial results for the seven-month transition period ending December 31, 2025, with revenue up 20% YoY to $75.5 million and Adjusted EBITDA more than quintupling to $13.1 million. Margins expanded significantly due to cost discipline and operational improvements, though net loss remains substantial. The company guided for $120–125 million in revenue for 2026, a decline from pro forma 2025 revenue of $141.4 million, citing customer-specific headwinds.
Key Financial Metrics
Key Facts
- Revenue for the seven-month transition period (May 26–Dec 31, 2025) was $75.5 million, up 20% YoY from $63.0 million.
- Gross profit margin improved to 31.4% from 25.9% in the prior-year period, driven by operational initiatives.
- Operating expenses fell 31% YoY to $24.4 million, primarily due to lower SG&A.
- Adjusted EBITDA surged to $13.1 million from $2.6 million in the prior-year period.
- Net loss narrowed to $18.0 million from $30.6 million, but remains significant.
- Company guided 2026 revenue of $120–125 million, below 2025 pro forma revenue of $141.4 million, due to customer supply shifts and delayed launches.
- Free cash flow was $3.6 million despite a $4.7 million preferred stock fee payment.
- ERP system launched in January 2026 to support future efficiency.
Financial Impact
Revenue growth of 20% and Adjusted EBITDA up $10.5M YoY, but 2026 guidance implies a ~12% revenue decline from 2025 pro forma levels.
Risk Factors
- Revenue guidance for 2026 is below 2025 pro forma levels, indicating near-term contraction.
- High customer concentration: loss of key customers or delays in their programs significantly impact outlook.
- $50.2 million in Series A Convertible Preferred Stock redemption risk starting June 2026, which could strain liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256216 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $4.44 $4.74 | ▲ +6.76% | ▲ +7.36% | $6.53 (+47.07%) |
Jul 2, 2026 13w ago | 8-K | $5.09 $4.36 | ▲ +14.34% | ▲ +13.93% | $6.53 (−28.29%) |
Jun 15, 2026 15w ago | Press Release | $5.49 $4.63 | ▼ −15.66% | ▼ −14.91% | $6.53 (+18.94%) |
Jun 5, 2026 17w ago | 8-K | $5.57 $5.05 | ▼ −9.34% | ▼ −10.97% | $6.53 (+17.24%) |
Jun 2, 2026 17w ago | Press Release | $5.45 $5.27 | ▼ −3.30% | ▼ −1.74% | $6.53 (+19.82%) |
May 6, 2026 21w ago | 8-K | $4.96 $5.67 | ▼ −14.31% | ▼ −11.53% | $6.53 (−31.65%) |
Mar 26, 2026 27w ago | Press Release | $3.87 $5.02 | ▲ +29.72% | ▲ +19.05% | $6.53 (+68.73%) |
Mar 16, 2026 28w ago | Press Release | $4.37 $5.20 | ▲ +18.99% | ▲ +15.21% | $6.53 (+49.43%) |
Mar 4, 2026 30w ago | Press Release | $7.02 $3.84 | ▼ −45.30% | ▼ −41.51% | $6.53 (−6.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access